| COVID-19 severe or critically | |
| COVID-19 severe or critically | |
| sarilumab | sarilumab Sanofi phase 3 outside US |
| sarilumab high dose (400mg) | Lescure ... |
| sarilumab low dose (200mg) | Lescure ... |
| 5515 | sarilumab Sanofi phase 3 US, 0 | 1 | 1 | 0 | risk of bias not avaialble | ||
| 5633 | ARI-RAF (Della-Torre), 2020 | 1 | 13 | 0 | not a RCT | risk of bias not avaialble | |
| 6465 | REMAP-CAP sarilumab, 2021 | 1 | 1 | 3 | high risk of bias |
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
